The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease

The Effect of Oral β- Glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver Echogenicity and Enzymes in Non Alcoholic Fatty Liver Disease Treating With Hypocaloric Diet and Vitamin E

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02178839

Enrollment

Registered

2014-07-01

Start date

2014-07-31

Completion date

Unknown

Last updated

2014-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease

Keywords

Non Alcoholic Fatty Liver Disease(NAFLD), β- glucan, Appetite, Insulin Resistance

Brief summary

The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with Hypocaloric Diet and Vitamin E.

Interventions

DIETARY_SUPPLEMENTβ- glucan

8.5 g/d of Oat Supplement Containing 3g β- glucan

DIETARY_SUPPLEMENTMaltodextrin

8.5 g/d Maltodextrin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Patients with Non Alcoholic Fatty Liver Disease From Both Sex * Age 18-55 years * BMI more than 25 Kg/m2

Exclusion criteria

* Alcohol Consumption * Pregnancy or lactation or menopause * Being a professional athlete * A history of cancer * Risk of high blood pressure (in the case of drug use) * Heart disease - cardiovascular, pulmonary, renal and diabetes * Liver transplantation and other chronic or acute Liver diseases such as hepatitis B, C and liver infections * The History of inherited disorders affecting the liver * A history of autoimmune disease * History of food allergies * Taking certain medications such as blood pressure control, statins, insulin sensitivity enhancers and hepatotoxic drugs

Design outcomes

Primary

Measure	Time frame	Description
Liver Echogenicity	8 weeks	Liver Echogenicity Describes by Grade,
Liver Enzymes	8 weeks	Enzymes ALP (Alkanin Phosphatase), ALT (Alanin Amino Transferase) and AST (Aspartat Amino Transferase)

Secondary

Measure	Time frame	Description
Insulin Resistance	8 weeeks	Describe by HOMA-IR (Homeostasis Model Assessment of Insulin Resistance)
Anthropometric Measurement WC	4weeks, 8 weeks	WC (waist circumference) measures by cm
Anthropometric Measurement WHR	4 weeks, 8 weeks	WHR (waist to hip ratio)
Anthropometric Measurement WHtR	4 weeks, 8 weeks	WHtR (waist to Height ratio)
Peptide YY (PYY) Hormone	8 weeks	Elayza kit
Cholecystokinin (CKK) Hormone	8 weeks	Elayza kit
Fasting Blood Sugar	8 weeks	FBS (Fasting Blood Sugar) mmol/lit
Anthropometric Measurement BMI	4 weeks, 8 weeks	BMI (Body Mass Index) kg/m2
Appetite	4 weeks, 8 weeks	NAS (numeric Analuge Scale) cm

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026